Bli medlem
Bli medlem

Du är här


BioStock: Abliva's NV354 targets fatal paediatric disease

Earlier this autumn, Abliva announced that NV354, the company's second candidate within the primary mitochondrial disease space, will progress to clinical phase. NV354 is initially being developed for the fatal Leigh syndrome, a disease that usually debuts before the age of 2 and patients often die before the age of 5. With NV354 about to join Abliva's leading candidate against primary mitochondrial disease, KL1333, in clinical development, BioStock takes a closer look at the candidate.

Read the full article at

This is a press release from BioStock - Connecting Innovation & Capital.

Författare Cision